Multidrug resistance: From bench to the bedside;Resistance a la chimiotherapie de type MDR en pratique clinique

Bulletin du Cancer

Volumn 83, Issue 8, 1996, Pages 609-618

  Oudard, S ^a   Marie, J P ^b   Pujade Lauraine, E ^a  

^a Serv Med I   (France)

^b HÔTEL DIEU   (France)

Author keywords

clinical trials; cyclosporin; MRP; multidrug resistance; verapamil

Indexed keywords

AMSACRINE; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BEPRIDIL; CALCIUM ANTAGONIST; CALMODULIN DERIVATIVE; CYCLOSPORIN; CYCLOSPORIN DERIVATIVE; DACTINOMYCIN; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GLYCOPROTEIN; IDARUBICIN; MITHRAMYCIN; MITOXANTRONE; NAVELBINE; NIGULDIPINE; PACLITAXEL; STEROID; TENIPOSIDE; TOPOTECAN; TRIMETREXATE; UNINDEXED DRUG; VERAPAMIL; VINBLASTINE; VINCRISTINE; CALCIUM CHANNEL BLOCKING AGENT; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; HUMAN; MULTIDRUG RESISTANCE; REVIEW; ANIMAL; DRUG POTENTIATION; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; PHENOTYPE; PRESCHOOL CHILD;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CHILD, PRESCHOOL; CYCLOSPORINE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MICE; P-GLYCOPROTEIN; PHENOTYPE; VERAPAMIL;

EID: 0030207471     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Almquist KC, Loe DW, Hipfner DR, Mackie JE, Cole SPC, Deeley RG. Characterization of the Mr 190,000 multidrug resistance protein (MRP) in drug-selected and transfected human tumor cells. Cancer Res 1995;55:102-10
2. Arceci RJ, Croop JM, Horwitz SB, Housman D. The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus. Proc Natl Acad Sci USA 1988;85:4350-4
3. Azzaria M, Schurr E, Gros P. Discrete mutations introduced in the predicted nucleotide-binding sites of the mdr1 gene abolish its ability to confer multidrug resistance. Mol Cell Biol 1989;9:5289-97
4. Baldini N, Scotlandi K, Barbanti-Brodano G et al. Expression of P-glycoprotein in high grade osteosarcomas in relation to clinical outcome. N Engl J Med 1995;333:1380-5
5. Belpomme D, Pujade-Lauraine E, Gauthier S et al. Continous low dose racemic verapamil significantly increases response rate and survival in patients treated by VDS and 5FU for anthracycline resistant metastatic breast carcinoma. Proc Am Assoc Cancer Res 1995;36:219
6. Boote DJ, Dennis IF, Twentyman PR. A phase I study of intravenous SDZ PSC-833 in patients with advanced cancer. Ann Oncol 1994;5:159-163
7. Bordow SB, Haber M, Madafiglio J, Cheung B, Marshall GM, Norris MD. Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res 1994;54:5036-40
8. Bourhis J, Benard J, Hartmann O, Boccon-Gibod L, Lemerle J, Riou G. Correlation of MDR1 gene expression with chemotherapy in neuroblastoma. J Natl Cancer Inst 1989;81:1401-5
9. Chan H, Thorner P, Haddad G, Ling V. Immunohistochemical detection of P-glycoprotein: pronostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 1990;8:689-704
10. Chan HSL, Haddad G, Thorner PS et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 1991;325:1608-14
11. Chauvenet L, Brouland JP, Pujade-Lauraine E et al. Immunohistochemical detection of P-glycoprotein is correlated with resistance to chemotherapy in NHL. Ann Oncol 1994;5:138
12. Cheng AL, Su JJ, Lee TC, Wang CH. Expression of P-glycoprotein and glutathione-S-transferase in recurrent lymphomas. The possible role of Epstein barr virus, immunophenotypes, and other predisposing factors. J Clin Oncol 1993;11:109-15
13. Cole SPC, Bhardwaj G, Gerlach JH et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650-4
14. Cordon-Cardo C, O'Brien JP, Casals D et al. Multidrug-resistance gene (Pglycoprotein) is expressed by endothelial cells at the bloodbrain barrier sites. Proc Natl Acad Sci USA 1989;86:695-8
15. Couvreur P, Roblot-Treupel L, Poupon MF, Brasseur F, Puisieux F. Nanoparticles as microcarriers for anticancer drugs. Adv Drug Delivery Rev 1990;5:209-30
16. Dalton WS, Grogan TM, Meltzer PS et al. Drug-resistance in multiple myeloma and non-hodgkin's lymphoma: detection of p-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989;7:415-24
17. Echizen H, Brecht T, Niedergesass S. The effect of dextro-, levo, and racemic verapamil on atrioventricular conduction in humans. Am Heart 1985;109:210-7
18. Fischer GA, Barlett NI, Lum BL et al. Phase I trial of taxol with high dose cyclosporine a modulator of multidrug resistance. Proc Am Soc Clin Oncol 1994;13:144
19. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci 1987;84:265-9
20. Ford J, Hait W. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990;42:156-99
21. Goldstein LJ, Galski H, Fojo A et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989;81:116-24
22. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SPC, Deeley RG. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 1994;54:357-61
23. Grogan TM, Spier CM, Salmon SE et al. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993;81:490-5
24. Hendrick AM, Harris AL, Cantwell BMJ. Verapamil with mitoxantrone for advanced ovarian cancer: A negative phase II trial. Ann Oncol 1991;2:71-2
25. Higgins CF. ABC transporters: from microorganims to man. Annu Rev Cell Biol 1992;8:67-113
26. Holmes JA, West RR. The effect of MDR-1 gene expression on outcome in acute myeloblastic leukaemia. Br J Cancer 1994;69:382-4
27. Holzmayer TA, Hilsenbeck S, Hoff DDV, Roninson IB. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small cell lung carcinomas. J Natl Cancer Inst 1992;84:1486-91
28. Hyafil F, Vergely C, Du-Vignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GFI20918, an acridone carboxamide derivative. Cancer Res 1993;53:1-8
29. Ishikawa H, Kawano MM, Okada K et al. Expression of DNA topoisomerase I and II gene and the genes possibly related to drug resistance in human myeloma cells. Br J Haematol 1993;83:68-74
30. Kerr DJ, GRaham J, Cumming J. The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol 1986;18:239-42
31. Krishnamachary N, Center MS. The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res 1993;53:3658-61
32. Linn S, Van-Kalken C, Van-Tellington O et al. Clinical and pharmacologie study of multidrug resistance reversal with vinblastine and bepridil. J Clin Oncol 1994;4:812-9
33. List AF, Spier C, Greer J et al. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 1993;11:1652-60
34. Lum BL, Kaubisch S, Yahanda AM et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 1992;10:1635-42
35. Ma L, Krishnamachary N, Center MS. Phosphorylation of multidrug resistance associated protein gene encoded protein P190. Biochemistry 1995;34:3338-43
36. Maenpaa J, Sipila P, Kangas L. Chemosensitizing effect of an antiestrogen, toremifene, on ovarian cancer. Gynecol Oncol 1992;46:292-7
37. Marie JP, Bastie JN, Coloma F et al. Cyclosporin A as a modifier agent in the salvage treatment of acute leukemia. Leukemia 1993;7:821-4
38. Mickisch GH, Merlino GT, Galski H, Gottesman MM, Pastan I. Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance. Proc Natl Acad Sci USA 1991;88:547-51
39. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 1991;9:17-24
40. Milroy R. A randomized clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. Br J Cancer 1993;68:813-8
41. Motzer RJ, Lyn P, Fischer P, et al. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J Clin Oncol 1995;13:1958-65
42. Mross K, Bohn C, Edler L. Randomized phase II study of single-agent epirubicin ± verapamil in patients with advanced metastatic breast cancer. Ann Oncol 1993;4:45-50
43. Mross K, Hamm K, Hossfeld DK. Effects of verapamil on the pharmacokinetics and metabolism of epirubicin. Cancer Chemother Pharmacol 1993;31:369-75
44. Ohi Y, Ohmori H, Shirahama T. Intravesical instillation of adriamycin in the presence or absence of verapamil for the treatment of supperficial bladder cancer. Cancer Chemother Pharmacol 1992;30:S50-4
45. Oudard S. La résistance multidrogue: bases biologiques et applications pratiques. Cancérologie Aujourd'hui 1992;3:20-5
46. Oudard S, Bouleuc C, Lotz JP et al. Phase I-II study combining high dose tamoxifene as a modulator of multidrug resistance with vinblastine and α2b interferon in metastatic kidney carcinoma. Proc Am Soc Clin Oncol 1994;13:243
47. Oudard S, Chevillard S, Lokiec F, Dorval T, Poupon MF, Pouillart P. A rapidly progressing leiomyosarcoma expressing drug resistance markers failed to respond to cyclosporin-A associated chemotherapy. Eur J Cancer 1994;30A:1594
48. Oudard S, Thierry A, Jorgensen TJ, Rahman A. Sensitization of multidrug-resistant colon cancer cells to doxorubicin encapsulated in liposomes. Cancer Chemother Pharmacol 1991;28:259-65
49. Ozols RF, Cunnion RE, Klecker RW et al. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 1987;5:641-7
50. Pireli SA, Sabattini E, Falini B et al. Immunohistochemical detection of the multidrug transport protein P-170 in human normal tissues and malignant lymphomas. Histopathology 1991;19:131-40
51. Plumb JA, Milroy R, Kaye SB. The activity of verapamil as a resistance modifier in vitro in drug resistant human tumor cell lines is not stereospecific. Biochem Pharmacol 1990;39:787-92
52. Regnier G, Dhainaut A, Atassi G. New triazine derivatives as potent modulators of multidrug resistance. J Med Chem 1992;35:2481-96
53. Rhodes T, Barrand MA, Twentyman PR. Modification by brefeldin A, bufilomycin A1 and 7-chloro-4-nitrobenz-2-oxa-1,3-diazole (NBD) of cellular accumulation and intracellular distribution of anthracyclines in the non-P-glycoprotein-mediated multidrug resistant cell line COR-L23/R. Br J Cancer 1994;70:60-6
54. Rodenburg CJ, Nooter K, Herweijer H et al. Phase II study of combining vinblastine and cyclosporin-A to circuvemt multidrug resistance in renal cell cancer. Ann Onc 1991;2:305-6
55. Rothenberg M, Ling V. Multidrug resistance: molecular biology and clinical relevance. J Natl Cancer Inst 1989;81:907-13
56. Rothenberg ML, Mickley LA, Cole DE et al. Expression of the MDR1/P-170 gene in patients with acute lymphoblastic leukemia. Blood 1989;74:1388-95
57. Salmon SE, Dalton WS, Grogan TM et al. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 1991;78:44-50
58. Salmon SE, Grogan TM, Miller T, Scheper R, Dalton WS. Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. J Natl Cancer Inst 1989;81:696-701
59. Scheithauer W, Schenk T, Czejka M. Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent D-verapamil. Br J Cancer 1993;68:8-9
60. Scheuten ME, Meusers P, Schröder J et al. Effect of dexniguldipine (B935) on the efficacy of daunorubicin (DNR) plus high-dose cytosine arabinoside (ara-C) in refractory acute myeloid leukemia (AML). Proc Am Soc Clin Oncol 1993;12:308
61. Schinkel AH, Smit JJM, Van-Tellingen O et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cells 1994;77:491-502
62. Sela S, Husain SR, Pearson JW, Longo DL, Rahman A. Reversal of multidrug resistance in human colon cancer cells expressing the human MDR1 gene by liposomes in combination with monoclonal antibody or verapamil. J Natl Cancer Inst 1995;87:123-8
63. Slapak CA, Mizunuma N, Kufe DW. Expression of the multidrug resistance associated protein and P-glycoproetion in doxorubicin-selected human myeloid leukemia cells. Blood 1994;84:3113-21
64. Smit JJM, Schinkel AH, Oude-Elferink RPJ, et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cells 1993;75:541-552
65. Sonneveld P, Durie BGM, Lokhorst HM et al. Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 1992;340:255-9
66. Sonneveld P, Marie JP. Phase I study of SDZ PSC833, a multidrug resistance modulating agent, in refractory multiple myeloma. Proc Am Assoc Cancer Res 1994;35:359
67. Sonneveld P, Schoester M, Leeuw KD. Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells. J Clin Oncol 1994;12:1584-91
68. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84:7735-8
69. Thierry AR, Vige D, Coughlin SS, Belli JA, Dritschilo A, Rahman A. Modulation of doxorubicin resistance in multidrug resistant cells by liposomes. FASEB 1993;7:572-9
70. Tolcher AW, Cowan KH, Solomon D et al. A phase I study of paclitaxel with R-verapamil in metastatic breast cancer. Proc Am Soc Clin Oncol 1994;13:139
71. Twentyman PT, Bleehen NM. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A. Eur J Cancer 1991;27:1639-42
72. Ueda K, Cardarelli C, Gottesman M, Pastan I. Expression of a full-length cDNA for the human MDR1 P-glycoprotein gene confers multidrug-resistance. Proc Natl Acad Sci USA 1987;84:3004-9
73. Veneroni S, Zaffanori N, Daidone MG, Benini E, Villa P., Silvestrini R. Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers. Eur J Cancer 1994;30A:1002-7
74. Verrelle P, Meissonnier F, Fonck Y et al. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 1991;82:111-6
75. Versantvoort CHM, Broxterman HJ, Feller N, Dekker H, Kuiper CM, Lankelma J. Probing daunorubicin accumulation defects in non-P-glycoprotein expressing multidrug-resistant cell lines using digitonin. Int J Cancer 1992;50:906-11
76. Verweij J, Herweijer H, Oosterom R et al. A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance. Br J Cancer 1991;64:361-4
77. Wilson WH, Bates SE, Fojo A et al. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 1995;13:1995-2004
78. Wishart GC, Bissett D, Paul J et al. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. J Clin Oncol 1994;12:1771-7
79. Yahanda AM, Adler KM, Fisher GA et al. Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 1992;10:1624-34